R&D expense · 2019–2025

Treace Medical Concepts R&D expense

$20.3M−1.5% · FY2025

Treace Medical Concepts (TMCI) reported $20.3M in R&D expense for fiscal 2025, −1.5% year on year.

$5.1M2019$5.8M2020$10.2M2021$13.6M2022$15.4M2023$20.6M2024$20.3M2025
Treace Medical Concepts — R&D expense, 2019–2025
Fiscal yearR&D expenseChangeFiling
FY20252025-12-31$20.3M−1.5%Open →
FY20242024-12-31$20.6M+33.3%Open →
FY20232023-12-31$15.4M+13.7%Open →
FY20222022-12-31$13.6M+33.1%Open →
FY20212021-12-31$10.2M+74.5%Open →
FY20202020-12-31$5.8M+15.3%Open →
FY20192019-12-31$5.1M—Open →

R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2019–2025 compound annual growth +26.0%

R&D expense at companies of similar size

Full ranking by R&D expense →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Treace Medical Concepts R&D expense |url=https://companiesranked.com/en/company/treace-medical-concepts/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Treace Medical Concepts R&D expense. CompaniesRanked. https://companiesranked.com/en/company/treace-medical-concepts/research-and-development-expense

BibTeX

@misc{companiesranked-en-company-treace-medical-concepts-research-and-development-expense-2026,
  author       = {{CompaniesRanked}},
  title        = {{Treace Medical Concepts R\&D expense}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/treace-medical-concepts/research-and-development-expense}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-K · 0001193125-26-079167 · February 27, 2026

{{cite web |title=Treace Medical Concepts R&D expense — 10-K (0001193125-26-079167) |url=https://www.sec.gov/Archives/edgar/data/1630627/000119312526079167/tmci-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Treace Medical Concepts overview